Phase 2 Alzheimer's Clinical Trials
17 recruitingPhase 2
What is a Phase 2 trial?
Phase 2 trials evaluate whether a treatment works for a specific condition and further assess its safety. These studies typically enroll several hundred participants and provide preliminary data on effectiveness.
Showing 1–17 of 17 trials
Recruiting
Phase 2
A Clinical Study of MK-2214 in People With Early Alzheimer's Disease (MK-2214-004)
Early Alzheimer's Disease
Merck Sharp & Dohme LLC340 enrolled71 locationsNCT07033494
Recruiting
Phase 2Phase 3
ACP-204 in Adults With Alzheimer's Disease Psychosis
Alzheimer's Disease Psychosis
ACADIA Pharmaceuticals Inc.1,074 enrolled145 locationsNCT06159673
Recruiting
Phase 2Phase 3
Safety and Efficacy of EXV-802 and EXV-801 in the Treatment of Agitation in Alzheimer's Disease Dementia
Agitation Associated With Alzheimer's Disease Dementia
Exciva GmbH300 enrolled14 locationsNCT07284472
Recruiting
Phase 2
An Open-Label Study of ML-007C-MA in Adults With Alzheimer's Disease Psychosis
Psychosis Associated With Alzheimer's Disease
MapLight Therapeutics210 enrolled3 locationsNCT07459660
Recruiting
Phase 2
A Phase 2 Study to Assess the Safety of EI-1071 and the Effects of EI-1071 on Neuroinflammation in Alzheimer's Disease Patients
Mild, Moderate, or Severe Alzheimer's Disease
Elixiron Immunotherapeutics (Hong Kong) Ltd.15 enrolled2 locationsNCT06745583
Recruiting
Phase 2
A Study to Assess the Efficacy and Safety of ML-007C-MA for the Treatment of Alzheimer's Disease Psychosis
Psychosis Associated With Alzheimer's Disease
MapLight Therapeutics300 enrolled26 locationsNCT06887192
Recruiting
Phase 2
Assessment of Foralumab Safety and Modulation of Microglial Activation in Alzheimer's Disease
DementiaAlzheimers DiseaseMild Cognitive Impairment Due to Alzheimer's Disease
Brigham and Women's Hospital16 enrolled1 locationNCT06489548
Recruiting
Phase 2
A Study to Assess the Efficacy and Safety of ITI-1284 in the Treatment of Psychosis Associated With Alzheimer's Disease
Psychosis Associated With Alzheimer's Disease
Intra-Cellular Therapies, Inc.370 enrolled65 locationsNCT06540833
Recruiting
Phase 2
A Study to Assess the Efficacy and Safety of ITI-1284 in the Treatment of Agitation Associated With Alzheimer's Dementia
Agitation Associated With Alzheimer's Dementia
Intra-Cellular Therapies, Inc.320 enrolled69 locationsNCT06651567
Recruiting
Phase 2
A Study of ONO-2020 in Patients With Agitation Associated With Alzheimer's Disease Dementia
Agitation Associated With Alzheimer's Disease Dementia
Ono Pharmaceutical Co., Ltd.90 enrolled38 locationsNCT06803823
Recruiting
Phase 1Phase 2
A Study to Assess the Effects of ACI-24.060 in Alzheimer's Disease and in Down Syndrome (ABATE Study)
Beta-AmyloidProdromal Alzheimer's DiseaseAmyloid Plaque+1 more
AC Immune SA176 enrolled19 locationsNCT05462106
Recruiting
Phase 2
A Study to Evaluate the Efficacy and Safety of TTYP01 Tablets in Early Symptomatic Alzheimer's Disease
ADEarly Alzheimer's Disease
Shanghai Auzone Biological Technology Co., Ltd.180 enrolled1 locationNCT07252440
Recruiting
Phase 2
Efficacy and Safety of Dimethyl Fumarate Among Patients with Mild Cognitive Impairment and Dementia Due to Alzheimer's Disease
MCIMCI-AD, Early Stage Alzheimer's Disease
Medical University of Lodz30 enrolled1 locationNCT06850597
Completed
Phase 2
A Phase II Extension study to assess the safety and tolerability of PBT2 and its effect on amyloid levels in the brains of patients with prodromal or mild Alzheimer's disease.
Prodromal Alzheimer's disease or mild Alzheimer's disease
Alterity Therapeutics40 enrolled3 locationsACTRN12613000777796
Completed
Phase 2
McCusker KARVIAH: Curcumin in Alzheimer's disease prevention
Prevention of Alzheimer's disease
McCusker Alzheimer's Research Foundation200 enrolled1 locationACTRN12613000681752
Recruiting
Phase 2
Open Label Extension Study to Evaluate the Safety, Tolerability and Cognitive Effects of VEL015 (Sodium Selenate) in Patients with Alzheimer’s Disease
Mild to moderate Alzheimer's disease
Velacor Therapeutics Pty Ltd40 enrolled3 locationsACTRN12613000170729
Completed
Phase 2
A Phase II clinical trial to assess the safety and tolerability of PBT2 and its effect on amyloid levels in the brains of patients with prodromal or mild Alzheimer's disease.
Prodromal Alzheimer's disease or mild Alzheimer's disease
Alterity Therapeutics42 enrolled5 locationsACTRN12611001008910